We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Automated Systems Detect Variant Hemoglobins

By LabMedica International staff writers
Posted on 13 Apr 2011
The detection performance of automated high-pressure liquid chromatography (HPLC) systems for variant hemoglobins has been compared. More...


The HPLC systems have become the method of choice for the evaluation of patients suspected with hemoglobinopathies, but they vary in their performance and ability to discriminate variant hemoglobins.

Scientists at the University of California Davis Health System, (Sacramento, CA, USA), evaluated the performance of two HPLC methods used in the detection of common hemoglobin (Hb) variants. They tested 377 samples, of which 99 were from patents with HbS, 32 with HbC, 78 with other hemoglobin variants or thalassemia, and 11 with increased hemoglobin A1c. The interpretations of each chromatograph produced by the HPLC systems were compared.

The two systems were the Variant, (Bio-Rad Laboratories, Hercules, CA, USA), and the Ultra2, (Trinity Biotech, Kansas City, MO, USA). Both the Variant and Ultra2 methods use a relatively short program that measures the separation process over approximately 4–6 minutes. The Ultra2 has a secondary feature that will reflex repeat test samples with abnormal peaks or unusual findings using a high-resolution method that observes the separation process over 6-8 minutes, allowing for better separation of the hemoglobin peaks.

There were no differences noted for hemoglobins A0, S, or C. There were significant differences between the HPLC methods for hemoglobins F, A2, and A1c. However, there was good concordance between normal and abnormal interpretations (97.9% and 96.2%, respectively). The authors concluded that both the Variant and Ultra2 HPLC methods were able to detect most common hemoglobin variants. There was better discrimination for fast hemoglobins, between hemoglobins E and A2, and between hemoglobins S and F using the Ultra2 HPLC method.

Hemoglobin variants are a result of genetic changes resulting in abnormal or dys-synchronous hemoglobin chain production, as in thalassemia or the generation of hemoglobin chain variants such as hemoglobin S, as seen in sickle cell anemia.

Automated high-pressure liquid chromatography (HPLC) systems have become the method of choice for the evaluation of hemoglobinopathies. With this method, samples are mixed with buffers and salts and injected through an ion exchange column where physical properties of the hemoglobin such as surface charge and hydrophilic group, are separated during migration. HPLC methods allow for better isolation of hemoglobin variants and are less subjective than electrophoretic methods.

The study was published in the April 2011 edition of the International Journal of Laboratory Hematology.

Related Links:

Bio-Rad Laboratories
Trinity Biotech
UC Davis



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.